Sorry to say but I found the presentation underwhelming. Its a complex story for sure but they need to simplify the message. Wouldn't be surprised if this drops into the low teens.
If Mark Chapman is so smart he would have figured this out about 10 years ago. Its complicated. Vytorin will be off patent before this gets figured out. Merck is not stupid, so put that into your moronic equation.
I think the best you can hope for is that they don't stop the study for futility during the interim analysis. If it is allowed to continue then that would suggest that the drug appears to be doing something beneficial.
A new paper published in Nature implicates triglycerides in increasing the risk of heart attack. The paper concludes: "these observations suggest that, as well as LDL cholesterol, disordered metabolism of triglyceride-rich lipoproteins contributes to MI risk."
The title of the paper is Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction.
There seems to be more and more scientific evidence being published in the past few years that show that elevated triglyceride levels increase risk of heart attack.
Speculation on my part but it looks to me like they are going to relocate their headquarters to the US. Risk losing a lot of the loyal Canadian investors that supported them on the way up..
From what I've seen there's no mention of Tekmira in the latest round of Ebola news. I have the sense that TKM-Ebola may be OK for the military but not for widespread use.
Why would ALNY buy them? Doesn't make any sense based on the history between the two companies.
I agree with a lot of what he covers although there is a lot of doom and gloom towards the end. They are going to need buckets of cash and a lot of luck to successfully develop their HBV portfolio.
If that is indeed then case then it tells me that they're afraid that any missteps in their ebola program could hurt their HBV program. Any safety signals or lack of efficacy in studies testing of their ebola treatment could slow down their HBV program.
I had the impression a few months ago that they weren't very concerned about their ebola program, probably becasue they were positioning themselves for HBV. For all we know they may be trying to license or sell it to another company right now.